Skye Bioscience, Inc. SEC filings SKYE
Skye Bioscience, Inc. has 631 filings in SEC EDGAR's recent list, going back to Mar 25, 2011. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 11, 2026 (agreement ended, officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| PRER14A | Filing | Oct 28, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 5, 2025 | — |
| CORRESP | Letter to the SEC | Dec 23, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2024 | — |
| EFFECT | Filing | May 17, 2024 | — |
| EFFECT | Filing | May 17, 2024 | — |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| CORRESP | Letter to the SEC | May 15, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| EFFECT | Filing | Apr 26, 2024 | — |
| EFFECT | Filing | Apr 10, 2024 | — |
| CERT | Filing | Apr 10, 2024 | — |
| 8-A12B | Filing | Apr 10, 2024 | — |
| CORRESP | Letter to the SEC | Apr 9, 2024 | — |
| CORRESP | Letter to the SEC | Apr 9, 2024 | — |
| CORRESP | Letter to the SEC | Apr 9, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2024 | — |
| D | Filing | Mar 27, 2024 | — |
| D | Filing | Feb 12, 2024 | — |
| D | Filing | Aug 29, 2023 | — |
| EFFECT | Filing | Aug 9, 2021 | — |
| CORRESP | Letter to the SEC | Aug 5, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 4, 2021 | — |
| EFFECT | Filing | Jul 31, 2020 | — |
| CORRESP | Letter to the SEC | Jul 29, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2020 | — |
| EFFECT | Filing | Mar 17, 2020 | — |
| EFFECT | Filing | Feb 13, 2020 | — |
| EFFECT | Filing | Dec 31, 2019 | — |
| AW | Filing | Dec 17, 2019 | — |
| EFFECT | Filing | Oct 28, 2019 | — |
| CORRESP | Letter to the SEC | Oct 25, 2019 | — |
| SEC STAFF LETTER | Filing | Aug 23, 2019 | — |
| SEC STAFF LETTER | Filing | Aug 14, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2019 | — |
| CT ORDER | Filing | Mar 26, 2019 | — |
| D | Filing | Nov 15, 2018 | — |
| CT ORDER | Filing | Aug 29, 2018 | — |
| EFFECT | Filing | Apr 16, 2018 | — |
| CORRESP | Letter to the SEC | Apr 13, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2018 | — |
| D/A | Filing | Feb 23, 2018 | — |
| D | Filing | Jan 25, 2018 | — |
| EFFECT | Filing | Dec 4, 2017 | — |
| CORRESP | Letter to the SEC | Dec 1, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2017 | — |
| D | Filing | Nov 14, 2017 | — |
| EFFECT | Filing | Mar 23, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 21, 2017 | — |
| CORRESP | Letter to the SEC | Mar 21, 2017 | — |
| EFFECT | Filing | Feb 8, 2017 | — |
| CORRESP | Letter to the SEC | Feb 7, 2017 | — |
| CT ORDER | Filing | Feb 6, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 30, 2017 | — |
| D | Filing | Jan 13, 2017 | — |
| EFFECT | Filing | Dec 5, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 1, 2016 | — |
| CORRESP | Letter to the SEC | Nov 30, 2016 | — |
| D | Filing | Nov 3, 2016 | — |
| EFFECT | Filing | Apr 25, 2016 | — |
| CORRESP | Letter to the SEC | Apr 21, 2016 | — |
| CT ORDER | Filing | Apr 21, 2016 | — |
| CT ORDER | Filing | Mar 1, 2016 | — |
| EFFECT | Filing | Nov 20, 2015 | — |
| CORRESP | Letter to the SEC | Nov 18, 2015 | — |
| CORRESP | Letter to the SEC | Nov 17, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2015 | — |
| CORRESP | Letter to the SEC | Oct 27, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2015 | — |
| D | Filing | Aug 27, 2015 | — |
| D | Filing | Apr 15, 2015 | — |
| D | Filing | Jan 9, 2015 | — |
| CT ORDER | Filing | Jan 2, 2015 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2014 | — |
| CORRESP | Letter to the SEC | Nov 18, 2014 | — |
| D | Filing | Nov 13, 2014 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2014 | — |
| SC 14F1 | Schedule 14f-1 | Oct 17, 2014 | — |
| 8-A12G | Form 8-a12g | Jan 28, 2014 | — |
| EFFECT | Filing | Jun 12, 2013 | — |
| CORRESP | Letter to the SEC | Jun 10, 2013 | — |
| UPLOAD | Letter from the SEC | May 3, 2013 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2013 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2013 | — |
| D/A | Filing | Jan 22, 2013 | — |
| D | Filing | Nov 8, 2012 | — |
| D/A | Filing | Nov 7, 2012 | — |
| D | Filing | Mar 25, 2011 | — |
Showing 91 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SKYE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1516551
- Former names
- Emerald Bioscience, Inc. (until Jan 7, 2021); Nemus Bioscience, Inc. (until Mar 14, 2019); LOAD GUARD LOGISTICS, INC. (until Oct 30, 2014); LOAD GUARD TRANSPORTATION, INC. (until Nov 7, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.